New anticonvulsant for Lennox-Gastaut syndrome

Eisai has launched Inovelon (rufinamide) for adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients from four years of age.

Lennox-Gastaut syndrome is a severe form of epilepsy, characterised by onset in early childhood of frequent seizures of multiple types.

Rufinamide is a broad-spectrum anticonvulsant that is structurally distinct from other antiepileptic drugs. It modulates the activity of neuronal sodium channels, prolonging their inactive state. Efficacy against seizures of Lennox-Gastaut syndrome has been demonstrated.

Further information: Eisai 020 8600 1400

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

New rapidly acting insulin launched

New rapidly acting insulin launched

Lyumjev is a new 'ultra rapidly acting' formulation...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Statin prescribing 'commonly breaching NICE guidance'

Statin prescribing 'commonly breaching NICE guidance'

Prescribing of suboptimal statin regimens is 'extremely...